{"public_id":"cl_04dd18024401b0e732b2e8202a908512","status":"active","superseded_by_public_id":null,"corpus_id":7120096,"text":"Median overall survival was 16 months after a median follow-up of 17.2 months.","confidence":0.97,"paper":{"corpus_id":7120096,"title":"A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer","url":"https://sah.borca.ai/papers/7120096"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.97,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_25f6b86ffe7e55e4fa273e3c4aeea648","name":"median follow-up","description":"The median duration over which patients were observed after treatment.","types":["follow-up measure"],"url":"https://sah.borca.ai/concepts/co_25f6b86ffe7e55e4fa273e3c4aeea648"},{"public_id":"co_91123d7a5ba1c45d3ef6eb9ee178e4ed","name":"advanced and metastatic bladder cancer","description":"Bladder cancer that is locally advanced, relapsed, or metastatic.","types":["disease"],"url":"https://sah.borca.ai/concepts/co_91123d7a5ba1c45d3ef6eb9ee178e4ed"},{"public_id":"co_fabf8c4500a8932d93f719a8a499d517","name":"overall survival","description":"The length of time patients remain alive after starting treatment.","types":["survival outcome"],"url":"https://sah.borca.ai/concepts/co_fabf8c4500a8932d93f719a8a499d517"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_04dd18024401b0e732b2e8202a908512"}